Publikationen

Evolution by innovation as a driving force to improve TCR-T therapies
Dolores J. Schendel. Front. Oncol. 2023, Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1216829
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy
Yngvar Fløisand , Mats Remberger, Iris Bigalke , Dag Josefsen , Helen Vålerhaugen , Else Marit Inderberg , Richard W Olaussen, Bjørn Tore Gjertsen, Rene Goedkoop, Christiane Geiger, Petra U Prinz, Frauke M Schnorfeil, Kai Pinkernell, Dolores J Schendel, Gunnar Kvalheim. Leukemia. 2023 Sep;37(9):1842-1849. doi: 10.1038/s41375-023-01980-3. Epub 2023 Jul 28.
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
Nadja Sailer*, Ina Fetzer*, Melanie Salvermoser*, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde+, and Daniel Sommermeyer+. Cancers 2022, 14, 1998. doi: 10.3390/cancers14081998
The T cell therapy field faces preclinical and translational R&D challenges as it targets more complex diseases
Gary Waanders, Silke Raffegerst, Petra Prinz-Schulz, Maja Buerdek. Cell & Gene Therapy Insights 2021; 7(1), 71–80; doi: 10.18609/cgti.2021.017
Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy
Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger. Journal for ImmunoTherapy of Cancer; 9(3); 25 March 2021; doi: 10.1136/jitc-2020-002035
Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
Anja Mösch, Silke Raffegerst, Manon Weis, Dolores J. Schendel and Dmitrij Frishman. Frontiers in Genetics Review published: 19 November 2019 doi: 10.3389/fgene.2019.01141
Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy
Schlenker, R., Olguín-Contreras, L., Leisegang, M., Schnappinger, J., Disovic, A., Rühland, S., Nelson, P., Leonhardt, H., Harz, H., Wilde, S., Schendel, D. Uckert, W., Willimsky, G. and Noessner, E. Cancer Research, 2017.
Assessment of cancer and virus antigens for cross-reactivity in human tissues
Jaravine, V., Raffegerst, S., Schendel, DJ., Frishman, D. Bioinformatics 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567.
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Nature Biotechnology 33, 402–407 (2015).
Expitope: a web server for epitope expression
Haase, K., Raffegerst, S., Schendel, D., Frishman, D. Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068.
Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells
Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Eur J Immunol. 2014 May 20 [Epub ahead of print].
The ABC’s of T cell receptor gene therapy
Schendel, D.J. and P.D. Greenberg. 2014. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014.
Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gross, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S., Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. J Immunother. 36(2):133-151.
Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity
Schendel, D.J. and Frankenberger, B. 2013. Oncoimmunology. 2013 Jan 1; 2(1):e22410.
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure
Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Oncoimmunology. 1(2): 129-140.
Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition
Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. J Immunol. 189(2): 598-605.
High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them
Wilde, S. and D.J., Schendel. 2012. Oncoimmunology. 1(9):1643-1644.
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. J. Clin. Invest. 120 (11): 3869-3877.
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity
Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Blood 114(10): 2131-2139.
Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay
Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Nat Med.; 7 (10):1159–1162.